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Background and purpose   Periosteal new bone formation and 
cortical hyperostosis often suggest an initial diagnosis of bone 
malignancy or osteomyelitis. In the present study, we investigated 
the cause of persistent bone hyperostosis in the offspring of two 
consanguineous parents. 
Methods   Clinical assessment, imaging, and direct sequencing 
were used to elucidate the etiology of the condition seen in the 
patient. 
Results   Radiological examination revealed periosteal reaction, 
diaphysitis, and cortical hyperostosis, suggesting osteomyelitis or 
a bone neoplasm. The clinical and radiological features were also 
reminiscent  of  hyperostosis  with  hyperphosphatemia  (HHS),  a 
rare autosomal recessive disease manifesting with recurrent, tran-
sient, and painful swelling of the long bones. The identification 
of two novel heterozygous pathogenic mutations in the GALNT3 
gene confirmed a diagnosis of HHS.
Interpretation   Molecular analysis represents an invaluable tool 
in the differential diagnosis of persistent cortical hyperostosis.  

Hyperostosis  with  hyperphosphatemia  (HHS;  Mendelian 
Inheritance in Man (MIM) 610233) is an extremely rare meta-
bolic disorder, characterized by repeated painful swelling of 
long bones accompanied by radiological findings of diaphy-
sitis such as cortical hyperostosis and periosteal new bone 
formation. These unspecific clinical and radiological findings 
may lead to delay in diagnosis and unnecessary and invasive 
diagnostic procedures (Mikati et al. 1981, Clarke et al. 1984, 
Narchi 1997).
Hyperphosphatemic  familial  tumoral  calcinosis  (HFTC; 
MIM211900) is another rare recessive disorder characterized 
by the development of large periarticular calcified masses, 
often associated with painful and mutilating skin ulcerations 
(Metzker et al. 1988). Both HFTC and HSS are associated 
with marked and persistent hyperphosphatemia resulting from 
increased renal tubular reabsorption of phosphate (Liu and 
Quarles 2007); the two diseases have rarely been reported 
in the same family (Narchi 1997). Accordingly, both condi-
tions have been found to result from mutations in the same 
gene, GALNT3, which encodes the enzyme UDP-N-acetyl-
alpha-D-galactosamine:polypeptide  N-acetylgalactosaminyl-
transferase 3 (ppGalNacT3) (Topaz et al. 2004, Frishberg et 
al. 2005). ppGalNacT3 has been found to mediate O-glyco-
sylation of FGF23 (Frishberg et al. 2007). FGF23 activity is 
regulated through the activity of a number of proteases that 
convert active FGF23 into two inactive proteolytic fragments 
(Liu and Quarles 2007). ppGalNacT3-mediated O-glycosyl-
ation is thought to protect FGF23 from proteolysis (Frishberg 
et al. 2007) and to be necessary for proper secretion of FGF23 
(Kato et al. 2006). 
We  describe  a  patient  with  HSS,  initially  diagnosed  as 
chronic osteomyelitis. This study underscores the complex-
ity of the differential diagnosis of cortical hyperostosis and 
the usefulness of non-invasive molecular diagnostics in such 
cases. 
Patients and methods
We studied a family of Turkish origin. All participants or their 
legal guardian provided written and informed consent accord-
ing to a protocol previously approved by the local institutional 
review board. 15 mL of blood was drawn from each subject, 
and DNA was extracted using a salt/chloroform extraction 
method. 
Mutational analysis
All exons and exon-intron boundaries of the GALNT3 and 
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(Benet-Pages et al. 2005, Frishberg et al. 2005). PCR ampli-
fication was performed using Taq polymerase and Q solution 
according to the manufacturer’s instructions (Qiagen, Valen-
cia, CA). Gel-purified amplicons were subjected to bidirec-
tional sequencing using Big Dye Terminator (PE Applied Bio-
systems, Foster City, CA). 
PCR-RFLP
To  verify  mutation  c.T2A  (see  Mutation Analysis  below), 
a 187-bp PCR fragment encompassing part of exon 1 was 
amplified using primers 5’- GTAGGACTGAATAGCTACTA-
ATAC-3’  and  5’-  GTGTAATTTTACTAGTCGCTTTAGGT-
GAGGC -3’, and digested in the presence of BsmI. To verify 
mutation  c.G839A,  a  470-bp  PCR  fragment  encompassing 
exon 4 was amplified using primers 5’- CAATAAATCTGAG-
GAAGAAAGAAATC-3’ and 5’- GTACACACTGTTTGCTT-
TATAGC-3’, and digested in the presence of BstOI. 
Results
Clinical findings
An 8-year old girl born to first-degree healthy consanguineous 
parents was admitted with painful swelling of the left lower 
leg that had lasted 10 days. Plain radiography showed a diaph-
yseal periosteal reaction (Figure 1a). Complete blood count 
was normal. Because of the absence of fever, a tumor was 
considered. MRI showed reduced signal intensity in the med-
ullary bone with similar changes in the periosteum and soft 
tissues on T1-weighted images (Figure 1b). On T2-weighted 
scans,  corresponding  areas  were  hyperintense.  Post-intra-
venous contrast images revealed enhancement of bone and 
adjacent soft tissues (Figure 1c). Antibiotic therapy (cephazo-
lin sodium, 500 mg twice a day intravenously for 2 weeks) 
was instituted for suspected osteomyelitis. Shortly thereafter, 
both symptoms and radiographic findings resolved. 7 months 
later, the girl was re-admitted with right lower leg pain and 
swelling.  Plain  films  and  MRI  showed  similar  findings  to 
those observed previously in the left leg. Mild hyperostosis 
of the tibia was also noted (Figure 1d–f). Routine blood tests 
were normal. With a presumptive diagnosis of malignancy or 
recurrent osteomyelitis, the patient underwent bone biopsy, 
which  showed  reactive  periostitis  and  normal  osteoblastic 
cells. No organisms were identified in the aspirate, and cul-
tures were sterile. Additional blood tests revealed increased 
serum  phosphate  (9.2  mg/dL;  age-adjusted  normal  values: 
3.6–5.9 mg/dL), normal serum creatinine, calcium, parathy-
roid hormone, and vitamin D levels. Serum phosphate levels 
were persistently high during a 12-month follow-up period. 
FGF23 C-terminal serum levels were elevated, as previously 
shown in HHS and HFTC (Topaz et al. 2004). Taken together, 
clinical, radiological, metabolic, and histopathologic findings 
suggested a diagnosis of HHS. 
Mutation analysis
HHS has recently been shown to result from mutations in the 
GALNT3 gene (Frishberg et al. 2005, 2007, Ichikawa et al. 
2007). To confirm a diagnosis of HHS, we therefore screened 
genomic DNA extracted from our patient for pathogenic muta-
tions in GALNT3. We  identified two heterozygous mutations: 
a maternal mutation, c.T2A, predicted to disrupt the initiation 
codon (p.M1?); and a paternal missense mutation, c.G839A 
(parental origin was determined by direct sequencing of DNA 
samples obtained from the two parents) (Figure 2a). This last 
mutation is predicted to not only result in the substitution of an 
aromatic tyrosine residue for a well-conserved aliphatic cyste-
ine residue (ConSeq score = 7; http://conseq.bioinfo.tau.ac.il) 
at amino acid position 280 (p.C280Y), but also to disrupt the 
Figure 1. (a) Radiograph demonstrating a subtle periosteal reaction in the midshaft of the left tibia (arrowhead). (b) A coronal T1-weighted 
sequence showing loss of normal fatty marrow in the tibia. (c) A post-contrast fat-suppressed coronal T1-weighted image revealing contrast 
enhancement in the marrow and adjacent soft tissues. (d) Radiograph showing a periosteal reaction (arrowheads) and medullary sclerosis of the 
right tibia. (e) An axial T1-weighted image demonstrating reduced bone marrow signal of the right tibia with adjacent soft tissue intensity. (f) A 
post-contrast fat-suppressed axial T1-weighted image revealing contrast enhancement in the marrow and juxtacortical soft tissue enhancement 
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consensus acceptor splice site of intron 3, leading to aberrant 
GALNT3 RNA processing.
We  used  PCR-RFLP  assays  to  verify  segregation  of  the 
mutations in the family and to exclude the 2 mutations from a 
panel of 50 control individuals (Figure 2b). 
Discussion
Our case remarkably illustrates the characteristic clinical and 
molecular features and also the diagnostic dilemmas associ-
ated with autosomal recessive HHS. 
The  recent  identification  of  GALNT3  mutations  in  both 
HFTC  and  HHS  patients  (Figure  2c)  (Topaz  et  al.  2004, 
Frishberg et al. 2005, 2007, Ichikawa et al. 2005, 2006, 2007, 
Campagnoli et al. 2006, Garringer et al. 2006, Specktor et al. 
2006, Barbieri et al. 2007, Garringer et al. 2007) has revealed 
that these metabolic disorders result primarily from aberrant 
regulation of FGF23-mediated phosphaturia (Kato et al. 2006, 
Frishberg et al. 2007). Two explanations have been advanced 
to explain the fact that mutations in GALNT3 lead to 2 distinct 
clinical phenotypes: HHS and HFTC. Firstly, mutations affect-
ing separate domains of the gene product may result in different 
phenotypes. This hypothesis is not, however, in line with the 
fact most mutations reported to date in GALNT3 are predicted 
(Topaz et al. 2004, Frishberg et al. 2005, 2007, Ichikawa et al. 
2005, 2006, 2007, Campagnoli et al. 2006, Garringer et al. 
2006, 2007, Specktor et al. 2006, Barbieri et al. 2007)—and 
in one case have been shown (Topaz et al. 2005)—to result 
in ppGalNacT3 deficiency. Moreover, a single founder muta-
tion has been shown to underlie both HFTC and HHS in two 
inbred Israeli populations (Frishberg et al. 2005), suggesting 
that still unknown modifiers play a pivotal role in the patho-
genesis of each disorder.
Radiological evidence of periosteal new bone formation and 
cortical hyperostosis are characteristically found in HHS, but 
they also often suggest malignancy or osteomyelitis (Talab 
and Mallouh 1988). A high degree of suspicion is warranted in 
order to avoid unnecessary procedures such as bone biopsies 
and nuclear scan. Imaging can be helpful to narrow the dif-
ferential diagnosis in such cases. MRI can demonstrate fluid 
accumulation in acute osteomyelitis due to reactive edema 
surrounding the infection process. Chronic multifocal osteo-
myelitis involves the metaphyses of multiple bones, and mani-
fest radiologically with a mixture of destructive and sclerotic 
areas. Langerhans cell histiocytosis shows a characteristic pat-
tern of a lytic lesion with a benign-appearing thick periosteal 
reaction. The diaphysis is more commonly involved than the 
metaphysis (Laor and Oestreich 1998). Approximately 20% of 
leukemia patients experience bone pain, which is classically 
periarticular  and  migratory.  Multiple,  small,  circumscribed 
osteolytic lesions often reflect leukemic involvement in bone 
tissue (Kobayashi et al. 2005). Typical skeletal abnormali-
ties in metastatic neuroblastoma consist of lytic, permeative 
lesions with metaphyseal involvement (Kaufman et al. 1978). 
Primary bone tumors usually have a soft tissue component 
(Laor and Oestreich 1998). 
In summary, despite the value of in-depth clinical and radio-
logical evaluation in cases suspected of being HHS, today 
molecular diagnosis represents the best way to reach a defini-
tive diagnosis, to avoid unnecessary interventions, and to pro-
vide affected individuals with adequate counseling. 
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